Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). Issue 3 (March 2018)

• Record Type: Journal Article
• Authors: Michel, Pierre; Boige, Valerie; Andre, Thierry; Aparicio, Thomas; Bachet, Jean Baptiste; Dahan, Laetitia; Guimbaud, Rosine; Lepage, Côme; Manfredi, Sylvain; Tougeron, David; Taieb, Julien; Selves, Janick; Le Malicot, Karine; Di Fiore, Frederic; Maillard, Emilie
• Is Part Of: Digestive and liver disease. Volume 50:Issue 3(2018)
• Page Start: 305
• Page End: 307
• Publication Date: 2018-03
• Subjects: Aspirin -- Colorectal cancer -- PI3KCA mutation; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2017.12.023
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Oxaliplatin-based adjuvant chemotherapy is standard of care for radically resected stage III colon cancer and an accepted option for high-risk stage II. Two recent retrospective studies strongly suggested that low-dose aspirin used (100 mg/d) after surgical resection of colorectal cancer with a PIK3CA mutation could act as a targeted therapy with a major protective effect on the risk of recurrence. We propose a double-blind randomized phase III study to evaluate aspirin (100 mg/d during 3 years or until recurrence) versus placebo. Main inclusion criteria are patients aged 18 or 20, stage III or high risk stage II. The primary endpoint of the study is 3-year disease-free survival (DFS). Hypotheses are to improve 3-years DFS from placebo: 72% to aspirin: 83% (HR = 0.56). 94 events and 264 patients with PIK3CA mutation are required. The secondary endpoints are DFS at 5 years, the overall survival rate at 5 years, grade 3–4 severe bleeding.